Ebola Virus Glycoprotein Domains Associated with Protective Efficacy
Open Access
- 10 June 2021
- Vol. 9 (6), 630
- https://doi.org/10.3390/vaccines9060630
Abstract
Ebola virus (EBOV) is the cause of sporadic outbreaks of human hemorrhagic disease in Africa, and the best-characterized virus in the filovirus family. The West African epidemic accelerated the clinical development of vaccines and therapeutics, leading to licensure of vaccines and antibody-based therapeutics for human use in recent years. The most widely used vaccine is based on vesicular stomatitis virus (VSV) expressing the EBOV glycoprotein (GP) (VSV-EBOV). Due to its favorable immune cell targeting, this vaccine has also been used as a base vector for the development of second generation VSV-based vaccines against Influenza, Nipah, and Zika viruses. However, in these situations, it may be beneficial if the immunogenicity against EBOV GP is minimized to induce a better protective immune response against the other foreign immunogen. Here, we analyzed if EBOV GP can be truncated to be less immunogenic, yet still able to drive replication of the vaccine vector. We found that the EBOV GP glycan cap and the mucin-like domain are both dispensable for VSV-EBOV replication. The glycan cap, however, appears critical for mediating a protective immune response against lethal EBOV challenge in mice.Funding Information
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (LV-IMVU)
This publication has 35 references indexed in Scilit:
- Development of Pandemic Vaccines: ERVEBO Case StudyVaccines, 2021
- Ebola virus diseaseNature Reviews Disease Primers, 2020
- Ebola Virus: Pathogenesis and Countermeasure DevelopmentAnnual Review of Virology, 2019
- ICTV Virus Taxonomy Profile: FiloviridaeJournal of General Virology, 2019
- Ebola: Lessons on Vaccine DevelopmentAnnual Review of Microbiology, 2018
- Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccinenpj Vaccines, 2016
- VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strainScience, 2015
- Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primatesProceedings of the National Academy of Sciences of the United States of America, 2013
- Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg virusesNature Medicine, 2005
- Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and ArenavirusesJournal of Virology, 2004